PMID- 37790261
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231005
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 16
DP  - 2023
TI  - Correlation Between Fibrinogen/Albumin and Diabetic Peripheral Neuropathy.
PG  - 2991-3005
LID - 10.2147/DMSO.S427510 [doi]
AB  - PURPOSE: This study aimed to examine the correlation between fibrinogen/albumin 
      (FAR) and diabetic peripheral neuropathy (DPN). PATIENTS AND METHODS: A total of 
      342 patients were included and categorized into either the DPN group or the 
      Non-DPN (NDPN) group based on their DPN status. The FAR index was determined by 
      calculating the ratio of fibrinogen (FIB) to serum albumin (ALB), multiplied by 
      100. The participants were then divided into a High-FAR group and a Low-FAR group 
      using the median FAR value as the threshold. Neurophysiological data were 
      collected from the participants, which included motor conduction velocity (MCV) 
      and sensory conduction velocity (SCV). RESULTS: The DPN group displayed higher 
      FAR levels [(DPN vs NDPN:6.72 (5.89,7.74) vs 5.94+/-1.14], in addition to slower 
      SCV and MCV data compared to the NDPN group. The high FAR group had a higher 
      prevalence of DPN (78.9% vs 55.6%) (P<0.05). There was a negative correlation 
      between FAR and NCV, including bilateral median nerve SCV, left ulnar nerve SCV, 
      bilateral median nerve MCV, bilateral common peroneal nerve MCV, bilateral tibial 
      nerve MCV, and left ulnar nerve MCV. FAR was revealed to be an independent risk 
      factor for the development of DPN in patients and demonstrated a greater 
      predictive value for DPN development in Type 2 diabetes mellitus (T2DM) compared 
      with FIB, HbA1c. CONCLUSION: The results suggest that monitoring FAR levels in 
      patients with T2DM could identify those at higher risk for developing DPN, making 
      the FAR index a valuable predictor of DPN development. Furthermore, since FAR has 
      an inverse relationship with NCV, it stands to reason that high FAR levels may 
      indicate nerve damage and slower conduction velocities. Thus, managing FAR could 
      prove beneficial in both preventing and delaying the onset of DPN in T2DM 
      patients.
CI  - (c) 2023 Ban et al.
FAU - Ban, Jiangli
AU  - Ban J
AD  - Graduate School of Hebei North University, Zhangjiakou, People's Republic of 
      China.
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's 
      Republic of China.
FAU - Pan, Xiaoyu
AU  - Pan X
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's 
      Republic of China.
AD  - Graduate School of Hebei Medical University, Shijiazhuang, People's Republic of 
      China.
FAU - Yang, Liqun
AU  - Yang L
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's 
      Republic of China.
FAU - Jia, Zhuoya
AU  - Jia Z
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's 
      Republic of China.
AD  - Graduate School of Hebei Medical University, Shijiazhuang, People's Republic of 
      China.
FAU - Zhen, Ruoxi
AU  - Zhen R
AUID- ORCID: 0009-0004-4517-8571
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's 
      Republic of China.
AD  - Graduate School of Hebei Medical University, Shijiazhuang, People's Republic of 
      China.
FAU - Zhang, Xueqing
AU  - Zhang X
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's 
      Republic of China.
AD  - Graduate School of North China University of Science and Technology, Tangshan, 
      People's Republic of China.
FAU - Chen, Shuchun
AU  - Chen S
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's 
      Republic of China.
AD  - Graduate School of Hebei Medical University, Shijiazhuang, People's Republic of 
      China.
LA  - eng
PT  - Journal Article
DEP - 20230927
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC10543934
OTO - NOTNLM
OT  - diabetic peripheral neuropathy
OT  - fibrinogen/albumin
OT  - type 2 diabetes mellitus
COIS- The authors report no conflicts of interest in this work.
EDAT- 2023/10/04 06:44
MHDA- 2023/10/04 06:45
PMCR- 2023/09/27
CRDT- 2023/10/04 04:01
PHST- 2023/06/25 00:00 [received]
PHST- 2023/09/16 00:00 [accepted]
PHST- 2023/10/04 06:45 [medline]
PHST- 2023/10/04 06:44 [pubmed]
PHST- 2023/10/04 04:01 [entrez]
PHST- 2023/09/27 00:00 [pmc-release]
AID - 427510 [pii]
AID - 10.2147/DMSO.S427510 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2023 Sep 27;16:2991-3005. doi: 10.2147/DMSO.S427510. 
      eCollection 2023.